From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases

From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases

Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully...

Full description

Bibliographic Details
Main Authors: Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Helia Hosseini, Sam Boroumand, Viola A. Stoegner, Ali-Farid Safi, Markus Perl, Samuel Knoedler, Bohdan Pomahac, Martin Kauke-Navarro
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
breast cancer
sarcoma
head and neck cancer
skin cancer
malignant melanoma
monoclonal antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/full

Similar Items